Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand

Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.